Home › Grants › PAR-25-051

Open

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Federal funding opportunity PAR-25-051 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes August 18, 2026

Posted
September 25, 2024
Closes
August 18, 2026
Cost sharing
No
Instrument
Cooperative Agreement
Assistance listing
93.121, 93.867, 93.279, 93.853, 93.242, 93.273, 93.213, 93.866
Category
Education, Health
Archives
September 23, 2026

Program funding history

Awards made under Assistance Listing 93.121 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$379.1M
FY2025 obligated
$378.9M
FY2026 (to date) obligated
$179.8M
Awards in window
2,319

Top recipients: Regents of the University of Michigan, Regents of the University of California, San Francisco, the, University of Southern California, University of Pittsburgh - of the Commonwealth System of Higher Education, Trustees of the University of Pennsylvania, the

Source: USAspending.gov · refreshed July 2026

Synopsis

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov   Full announcement

Agency contact: National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts